Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) Research & Development (2016 - 2025)

Historic Research & Development for Neurocrine Biosciences (NBIX) over the last 15 years, with Q4 2025 value amounting to $258.2 million.

  • Neurocrine Biosciences' Research & Development rose 3911.64% to $258.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.0 billion, marking a year-over-year increase of 3892.76%. This contributed to the annual value of $1.0 billion for FY2025, which is 3892.76% up from last year.
  • According to the latest figures from Q4 2025, Neurocrine Biosciences' Research & Development is $258.2 million, which was up 3911.64% from $250.0 million recorded in Q3 2025.
  • Over the past 5 years, Neurocrine Biosciences' Research & Development peaked at $263.2 million during Q1 2025, and registered a low of $73.2 million during Q1 2021.
  • Moreover, its 4-year median value for Research & Development was $159.4 million (2024), whereas its average is $170.2 million.
  • Per our database at Business Quant, Neurocrine Biosciences' Research & Development plummeted by 754.02% in 2021 and then skyrocketed by 6511.92% in 2025.
  • Over the past 4 years, Neurocrine Biosciences' Research & Development (Quarter) stood at $92.7 million in 2021, then skyrocketed by 48.33% to $137.5 million in 2023, then skyrocketed by 34.98% to $185.6 million in 2024, then surged by 39.12% to $258.2 million in 2025.
  • Its last three reported values are $258.2 million in Q4 2025, $250.0 million for Q3 2025, and $244.3 million during Q2 2025.